SEGMENT RESULTS - Schedule of Disaggregation of Revenues (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue
TOTAL REVENUES, NET	$ 2,318,875,000	$ 2,993,206,000	$ 2,903,074,000
Product line revenue reporting threshold	$ 25,000,000	$ 25,000,000
XIAFLEX® | Revenue from Contract with Customer Benchmark | Product Concentration Risk
Disaggregation of Revenue
Concentration risk, percentage	19.00%	14.00%	11.00%
VASOSTRICT® | Revenue from Contract with Customer Benchmark | Product Concentration Risk
Disaggregation of Revenue
Concentration risk, percentage	11.00%	30.00%	27.00%
Varenicline Tablets | Revenue from Contract with Customer Benchmark | Product Concentration Risk | Maximum
Disaggregation of Revenue
Concentration risk, percentage	13.00%
Branded Pharmaceuticals
Disaggregation of Revenue
TOTAL REVENUES, NET	$ 851,142,000	$ 893,617,000	$ 781,780,000
Branded Pharmaceuticals | Specialty Products
Disaggregation of Revenue
TOTAL REVENUES, NET	621,700,000	633,150,000	497,078,000
Branded Pharmaceuticals | XIAFLEX®
Disaggregation of Revenue
TOTAL REVENUES, NET	438,680,000	432,344,000	316,234,000
Branded Pharmaceuticals | SUPPRELIN® LA
Disaggregation of Revenue
TOTAL REVENUES, NET	113,011,000	114,374,000	88,182,000
Branded Pharmaceuticals | Other Specialty
Disaggregation of Revenue
TOTAL REVENUES, NET	70,009,000	86,432,000	92,662,000
Branded Pharmaceuticals | Established Products
Disaggregation of Revenue
TOTAL REVENUES, NET	229,442,000	260,467,000	284,702,000
Branded Pharmaceuticals | PERCOCET®
Disaggregation of Revenue
TOTAL REVENUES, NET	103,943,000	103,788,000	110,112,000
Branded Pharmaceuticals | TESTOPEL®
Disaggregation of Revenue
TOTAL REVENUES, NET	38,727,000	43,636,000	35,234,000
Branded Pharmaceuticals | Other Established
Disaggregation of Revenue
TOTAL REVENUES, NET	86,772,000	113,043,000	139,356,000
Sterile Injectables
Disaggregation of Revenue
TOTAL REVENUES, NET	589,633,000	1,266,097,000	1,238,847,000
Sterile Injectables | VASOSTRICT®
Disaggregation of Revenue
TOTAL REVENUES, NET	253,696,000	901,735,000	785,646,000
Sterile Injectables | ADRENALIN®
Disaggregation of Revenue
TOTAL REVENUES, NET	114,304,000	124,630,000	152,074,000
Sterile Injectables | Other Sterile Injectables
Disaggregation of Revenue
TOTAL REVENUES, NET	221,633,000	239,732,000	301,127,000
Generic Pharmaceuticals
Disaggregation of Revenue
TOTAL REVENUES, NET	795,457,000	740,586,000	783,110,000
International Pharmaceuticals
Disaggregation of Revenue
TOTAL REVENUES, NET	$ 82,643,000	$ 92,906,000	$ 99,337,000
International Pharmaceuticals | Revenue from Contract with Customer Benchmark | Product Concentration Risk | Maximum
Disaggregation of Revenue
Concentration risk, percentage	5.00%	5.00%